Nammi Therapeutics is an immunotherapy company that develops nano-enabled chemo-immunotherapy for the treatment of cancer.
Nammi Therapeutics has raised $1.0M in total funding. The most recent round was Series B. The last funding was announced in August 2024.
Nammi Therapeutics's investors include Myeloma Investment Fund.
Nammi Therapeutics is headquartered in Los Angeles, United States.
Nammi Therapeutics is an immunotherapy company that develops nano-enabled chemo-immunotherapy for the treatment of cancer.
Nammi Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nammi Therapeutics — Funding & Investors." VCBacked, August 6, 2024, https://www.vcbacked.co/company/nammi-therapeutics. Accessed September 25, 2026.
VCBacked. (2024). Nammi Therapeutics — Funding & Investors. Retrieved September 25, 2026, from https://www.vcbacked.co/company/nammi-therapeutics
{{cite web |title=Nammi Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nammi-therapeutics |website=VCBacked |access-date=September 25, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated